hydroxychloroquine has been researched along with Biliary Atresia in 1 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Biliary Atresia: Progressive destruction or the absence of all or part of the extrahepatic BILE DUCTS, resulting in the complete obstruction of BILE flow. Usually, biliary atresia is found in infants and accounts for one third of the neonatal cholestatic JAUNDICE.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Heinz, N | 1 |
Griesemer, A | 1 |
Kinney, J | 1 |
Vittorio, J | 1 |
Lagana, SM | 1 |
Goldner, D | 1 |
Velasco, M | 1 |
Kato, T | 1 |
Lobritto, S | 1 |
Martinez, M | 1 |
1 other study available for hydroxychloroquine and Biliary Atresia
Article | Year |
---|---|
A case of an Infant with SARS-CoV-2 hepatitis early after liver transplantation.
Topics: Biliary Atresia; COVID-19; COVID-19 Testing; Female; Graft Rejection; Humans; Hydroxychloroquine; Im | 2020 |